GlassScriptPhysician profile
Michael J Whiteley
NPI 1295720795
$3,788.49
in general payments reported to CMS, 2019-2025
36 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $131 · 2021: $513 · 2022: $625 · 2023: $709 · 2024: $700 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $654.71 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $367.93 | 2019-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $277.76 | 2019-2025 | Tymlos |
| Abbvie INC. | $258.54 | 2021-2025 | Ubrelvy |
| Amgen INC. | $246.25 | 2021-2025 | Repatha, Otezla, Krystexxa |
| Merz North America, INC. | $239.06 | 2019 | |
| Novo Nordisk INC | $226.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $153.58 | 2021-2024 | Xarelto, Spravato |
| Pfizer INC. | $152.64 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $151.35 | 2019-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $120.78 | 2022-2024 | |
| Exact Sciences Corporation | $93.97 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $86.43 | 2021-2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $74.62 | 2021-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $73.83 | 2023-2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.22 | 2019-2023 | Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $57.05 | 2021 | |
| Antares Pharma, INC. | $40.81 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $38.77 | 2025 | Lagevrio |
| Sanofi-Aventis U.S. LLC | $37.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.10 | 2022-2025 | Jardiance |
| Mylan Specialty L.P. | $35.34 | 2021 | |
| Inspire Medical Systems, INC. | $35.10 | 2024 | Inspire |
| Eisai INC. | $32.54 | 2021 | |
| Sumitomo Pharma America, INC. | $32.05 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $28.63 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $27.57 | 2021-2025 | Contrave |
| Kyowa Kirin, INC. | $27.31 | 2024 | Crysvita |
| Corcept Therapeutics | $21.24 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $20.47 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.04 | 2024 | Nuzyra |
| Hologic Sales and Service, LLC | $15.10 | 2021 | |
| Dexcom, INC. | $13.22 | 2022 | |
| Cequr Corporation | $13.12 | 2023 | Cequr Simplicity |
| Sunovion Pharmaceuticals INC. | $12.40 | 2021 | |
| Allergan, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Whiteley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.